Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AIM Vaccine Co., Ltd. Class H ( (HK:6660) ) has shared an update.
AIM Vaccine Co., Ltd. has announced the appointment of Mr. Shaojun Jia as the new President of the company, effective April 17, 2025. Mr. Jia, who previously served as the Executive President and Chief Operating Officer, will now oversee the daily operational management of the company. This leadership change is expected to impact the company’s operational dynamics and could influence its strategic direction in the vaccine industry.
More about AIM Vaccine Co., Ltd. Class H
AIM Vaccine Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, focusing on the vaccine industry. The company is engaged in the development and production of vaccines, serving a critical role in the healthcare sector.
YTD Price Performance: -47.72%
Average Trading Volume: 6,404,183
Technical Sentiment Signal: Buy
Find detailed analytics on 6660 stock on TipRanks’ Stock Analysis page.